Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Similar virologic response after initiation of triple-class antiretroviral therapy in primary and chronic HIV infection.

Grijsen ML, Holman R, Wit FW, Gras L, Lowe SH, Brinkman K, de Wolf F, Prins JM.

AIDS. 2012 Sep 24;26(15):1974-7. No abstract available.

PMID:
22992579
2.

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT.

Ann Intern Med. 1997 Jun 15;126(12):929-38.

PMID:
9182469
3.
4.
5.

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Muñoz E, Muñoz-Fernandez MA, Moreno S.

AIDS. 2012 Sep 24;26(15):1885-94.

PMID:
22992577
6.
7.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
8.

Predictive value of HIV-1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment-experienced patients.

Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, Holodniy M.

HIV Med. 2012 Jul;13(6):345-51. doi: 10.1111/j.1468-1293.2011.00981.x. Epub 2012 Jan 26.

9.

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC.

AIDS. 2000 Jun 16;14(9):F83-93.

PMID:
10894268
10.

Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group.

Spritzler J, Mildvan D, Russo A, Asthana D, Livnat D, Schock B, Kagan J, Landay A, Haas DW; Adult AIDS Clinical Trials Group..

Clin Infect Dis. 2003 Aug 15;37(4):551-8. Epub 2003 Jul 29.

PMID:
12905140
11.

Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.

Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC.

N Engl J Med. 2001 Mar 8;344(10):720-5.

12.

Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L.

Ann Intern Med. 2000 Sep 19;133(6):401-10.

PMID:
10975957
13.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
14.

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

Kravcik S, Gallicano K, Roth V, Cassol S, Hawley-Foss N, Badley A, Cameron DW.

J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):371-5.

PMID:
10458617
15.
16.

Anti-HIV-1 intermittent drug intensification in HIV-1-infected patients naive for antiretrovirals.

Rusconi S, Argenteri B, Galli M, d'Arminio-Monforte A, Moroni M.

Antivir Ther. 1999;4(3):183-4. No abstract available.

PMID:
12731759
17.

[Antiretroviral therapy 1994 versus 2004. The reality illustrated by typical cases].

Kuhlmann B, Trein A.

MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:72-3. German. No abstract available.

PMID:
15373057
18.

Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy.

Bennett KK, DeGruttola VG, Marschner IC, Havlir DV, Richman DD.

J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):20-6.

PMID:
12352146
19.

Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy.

Mezzaroma I, Carlesimo M, Pinter E, Muratori DS, Di Sora F, Chiarotti F, Cunsolo MG, Sacco G, Aiuti F.

Clin Infect Dis. 1999 Dec;29(6):1423-30.

PMID:
10585790
20.

Supplemental Content

Support Center